Titanium Dioxide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Titanium Dioxide: From Sunscreen Use to Drug-Induced Osteoporosis
One-Sentence Summary
Titanium dioxide is a UV-blocking agent, registered in Australia as an ingredient in a sunscreen lotion (Sunsense Comfort SPF 50+). The TxGNN model predicts it may be effective for drug-induced osteoporosis, but there are 0 clinical trials and 0 publications supporting this prediction. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the data compiled for this report (the ARTG entry has no indication text) |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Titanium dioxide is an inert mineral pigment and UV-blocking agent used in sunscreens. No known pharmacological action on bone remodelling has been identified.
The relationship between the original use (topical sun protection) and the predicted indication (drug-induced osteoporosis) is not apparent. Titanium is used in orthopaedic implants, but that reflects osseointegration of the metal, not a therapeutic effect of titanium dioxide on osteoporosis. The very high TxGNN score (1.0000) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. With no supporting clinical or literature evidence, it should be treated with caution.
Other predictions for this drug are also unsupported. They include diabetic retinopathy (including severe nonproliferative disease), several cataract types (diabetic, cortical, mature, immature, tetanic and craniostenosis-related) and diabetes-associated cataract. For diabetic retinopathy, five publications were retrieved, but they describe titanium dioxide as a laboratory or imaging tool (such as extracellular vesicle purification, retinal imaging and an eye phantom), not as a treatment. Titanium dioxide nanoparticles also carry known oxidative-stress and toxicity concerns.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for drug-induced osteoporosis.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13188D | Sunsense Comfort SPF 50+ | Lotion 1.8%-4%-8%-8%-2.5%, 125 mL | Not stated |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information. No warnings, contraindications or drug interaction data were available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is purely computational (L5), with no clinical trials, no relevant publications and no plausible mechanism linking titanium dioxide to bone health. The only registered product is a topical sunscreen, which is not a plausible route for treating osteoporosis.
To proceed, the following is needed:
- Mechanism of action data and any preclinical evidence of an effect on bone metabolism
- Approved indication text and safety information (warnings, contraindications) from the product label
- Assessment of route compatibility, since the registered product is a topical lotion
- Evidence of safety and toxicity for any systemic exposure, given the oxidative-stress concerns with titanium dioxide nanoparticles
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.